New Delhi, Dec 27 (IANS) There is an urgent need for improved diagnostic tools and targeted therapies to address the gap in care for patients with severe asthma, specifically for those with T-helper cell type 2 (T2)-low asthma, a subtype lacking typical inflammatory biomarkers, according to a report on Friday.
T2-low asthma presents unique challenges due to the absence of eosinophils and immunoglobulin E (IgE), which complicates both diagnosis and treatment. And treatments currently available are primarily focused on eosinophilic and allergic inflammation. This leaves patients with non-eosinophilic or neutrophilic asthma without adequate options.
The report by GlobalData, a data and analytics company, showed that while T2-high asthma has benefitted from targeted biologic treatments, T2-low asthma remains largely underserved.
“The current treatment landscape for severe asthma has made significant strides, particularly for T2-high asthma. However, T2-low asthma remains largely under-researched and under-treated. There is an urgent need for both reliable biomarkers and therapies targeting this neglected subset of asthma patients,” said Sravani Meka, Senior Pharmaceutical Analyst at GlobalData.
While Meka lauded emerging therapies, she called for more research and development to help people with T2-high asthma. She also highlighted the need to develop new diagnostic tools that help distinguish T2-low asthma from other forms of asthma. Often people with T2-high asthma remain undiagnosed or misdiagnosed, resulting in delayed and inadequate treatment.
The report noted that despite the availability of biologics, many patients struggle with inhaler technique, high medication costs, and inconsistent use, resulting in poor asthma control, and preventing optimal treatment outcomes.
The report urged for addressing patient education on inhaler use and improving access to treatments for enhancing asthma control.
“To truly address the needs of T2-low asthma patients, there must be a concerted effort to improve diagnostics, develop targeted treatments, and ensure better access to care. Only then can we achieve significant improvements in asthma management for all patients, regardless of their asthma subtype,” Meka said.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
